Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.51 |
| ▸ | DRD4 | P21917 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | DRD1 | P21728 | 2/20 | 0.51 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3829971 | 1.00 | DRD2 (0.51) | DRD2DRD4DRD3DRD1ADRA1D | |
| Hydrochloric Acid SCHEMBL6547743 | 0.98 | DRD2 (0.50) | DRD2DRD4DRD3DRD1ADRA1D | |
| Bromide SCHEMBL7037393 | 0.98 | DRD2 (0.50) | DRD2DRD4DRD3DRD1ADRA1D | |
| SCHEMBL2956868 | 0.84 | ADRA1D (0.49) | DRD2DRD4DRD3DRD1ADRA1D | |
| SCHEMBL11520474 | 0.83 | DRD2 (0.57) | DRD2DRD4DRD3DRD1ADRA1D | |
| Bromide SCHEMBL6008428 | 0.81 | DRD2 (0.50) | DRD2DRD4DRD3DRD1ADRA1D | |
| SCHEMBL7424155 | 0.80 | DRD2 (0.71) | DRD2DRD4DRD3DRD1ADRA1D | |
| SCHEMBL7424159 | 0.80 | DRD2 (0.71) | DRD2DRD4DRD3DRD1ADRA1D | |
| SCHEMBL14360233 | 0.80 | DRD2 (0.67) | DRD2DRD4DRD3DRD1CA1 | |
| Bromide SCHEMBL7336392 | 0.79 | DRD2 (0.69) | DRD2DRD4DRD3DRD1ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040102652-A1 | Optically active2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them | CHIESI FARMACEUTICI S.P.A. (IT) | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102652-A1 | Optically active2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them | AADAT, AASDHPPT, AAAS | DRD2 594/4885DRD4 857/4885DRD3 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.